Gynecologic cancers account for nearly 40% of all cancer incidence and >30% of all cancer mortality in women worldwide. In recent years, there have been significant advancements in the classification of gynecologic tumors as well as the refinement of biomarker testing of prognostic and therapeutic significance. Human papillomavirus testing, DNA mismatch repair, HER2 and PD-L1 testing and homologous recombination testing have all seen advancements in recent years. It is the combination of an accurate histopathologic diagnosis and biomarker status that ensures timely and optimal therapy for each patient with gynecologic cancer.

Learning Objectives: 
• Review indications for biomarker testing in gynecologic cancers 
• Describe the current prognostic and predictive biomarkers in gynecologic pathology 
• Review guidelines for testing and interpretation of prognostic and predictive biomarkers in gynecologic cancers 
• Summarize challenges in biomarker testing in gynecologic pathology